# Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care

Source: https://onco.cc/key-papers/paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025/  
OnCo record `paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Of nearly 2,000 people with gallbladder cancer seen at Mumbai's Tata Memorial in four years, six in ten already had spread when they arrived and only one in six could be offered treatment aimed at cure.

## Summary

Prospective hospital registry of all patients presenting with presumed gallbladder cancer to Tata Memorial Hospital from January 2019 to December 2022: 1,950 patients, of whom 1,441 (73.9 percent) came from the Gangetic belt and a further 209 (10.7 percent) were migrants from it (84.6 percent together); over 55 percent were from lower socioeconomic classes. At presentation 60 percent had metastatic disease; 318 (16.3 percent) were eligible for curative-intent therapy and 132 (6.8 percent) did not complete planned treatment, with dropout linked to male sex and unemployment. After a median follow-up of 38.2 months, median overall survival was 58.2 months for early-stage and 4.2 months for metastatic disease.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Tags: gallbladder-evidence
- Journal: Cancer Epidemiology
- Year: 2025
- DOI: 10.1016/j.canep.2025.102958
- Authors: Patkar S, Shah TM, Varty G, et al.
- Findings: 1,950 patients in four years; 84.6 percent from or migrated from the Gangetic belt.; 60 percent metastatic at presentation; 16.3 percent eligible for curative-intent treatment; 6.8 percent did not complete treatment.; Median overall survival 58.2 months early-stage vs 4.2 months metastatic.
- What it means: The clearest statement of where the burden falls and why late presentation, not drug choice, decides most outcomes in high-incidence regions; it is also the home of the POLCAGB trial.
- Caveats: Single referral centre; patients who never reach a cancer centre are not counted.; Stage distribution reflects referral patterns.

## Sources

- Cancer Epidemiol 2025: https://doi.org/10.1016/j.canep.2025.102958
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41237686/

## Connected records

- cancers: [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- institutions: [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- journals: [Cancer epidemiology](https://onco.cc/journals/cancer-epidemiology/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)
- ideas: [Risk-targeted ultrasound screening in high-incidence regions, tested against usual care](https://onco.cc/ideas/idea-gbc-risk-targeted-ultrasound-in-high-incidence-regions/)

---
JSON: https://onco.cc/api/v1/entities/paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025.json